Taxanes in the Treatment of Advanced Gastric Cancer

被引：16

作者：

Kang, Byung Woog ^{[1
]}

Kwon, Oh-Kyoung ^{[2
]}

Chung, Ho Young ^{[2
]}

Yu, Wansik ^{[2
]}

Kim, Jong Gwang ^{[1
]}

机构：

[1] Kyungpook Natl Univ, Dept Oncol Hematol, Med Ctr, Sch Med,Canc Res Inst, 807 Hogukno, Daegu 41404, South Korea

[2] Kyungpook Natl Univ, Dept Surg, Kyungpook Natl Univ Hosp, Sch Med, Daegu 41494, South Korea

来源：

MOLECULES | 2016年 / 21卷 / 05期

基金：

新加坡国家研究基金会;

关键词：

gastric cancer; taxanes; paclitaxel; docetaxel; chemotherapy; PHASE-III TRIAL; ALBUMIN-BOUND PACLITAXEL; 2ND-LINE CHEMOTHERAPY; 1ST-LINE THERAPY; PLUS CISPLATIN; ANTITUMOR-ACTIVITY; OPEN-LABEL; FLUOROURACIL; DOCETAXEL; ADENOCARCINOMA;

D O I：

10.3390/molecules21050651

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

Although rapid advances in treatment options have improved the prognosis of advanced gastric cancer (AGC), it remains a major public health problem and the second leading cause of cancer-related deaths in the world. Taxanes (paclitaxel and docetaxel) are microtubule stabilizing agents that inhibit the process of cell division, and have shown antitumor activity in the treatment of AGC as a single or combination chemotherapy. Accordingly, this review focuses on the efficacy and tolerability of taxanes in the first-or second-line chemotherapy setting for AGC.

引用

页数：10

共 50 条

[1] The treatment of advanced gastric cancer: New findings on the activity of the taxanes
Van Cutsem, E
ONCOLOGIST, 2004, 9 : 9 - 15
[2] Influence of Taxanes on Treatment Sequence in Gastric Cancer
Lorenzen, Sylvie
Stahl, Michael
Hofheinz, Ralf-Dieter
Al-Batran, Salah-Eddin
Lordick, Florian
ONCOLOGY RESEARCH AND TREATMENT, 2020, 43 (1-2) : 42 - 47
[3] Advanced gastric cancer. Entrance to the official scene of taxanes
Artru, Pascal
Lledo, Gerard
ACTA ENDOSCOPICA, 2007, 37 (02) : 248 - 249
[4] Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Takashi Nishimura
Satoru Iwasa
Kengo Nagashima
Natsuko Okita
Atsuo Takashima
Yoshitaka Honma
Ken Kato
Tetsuya Hamaguchi
Yasuhide Yamada
Yasuhiro Shimada
Narikazu Boku
Gastric Cancer, 2017, 20 : 655 - 662
[5] IRINOTECAN AS A THIRD-LINE TREATMENT OF ADVANCED GASTRIC CANCER AFTER FAILURE OF FLUOROPYRIMIDINE, PLATINUM, AND TAXANES
Nishimura, Takashi
Iwasa, Satoru
Shoji, Hirokazu
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
ANNALS OF ONCOLOGY, 2014, 25
[6] Irinotecan monotherapy as third-line treatment for advanced gastric cancer refractory to fluoropyrimidines, platinum, and taxanes
Nishimura, Takashi
Iwasa, Satoru
Nagashima, Kengo
Okita, Natsuko
Takashima, Atsuo
Honma, Yoshitaka
Kato, Ken
Hamaguchi, Tetsuya
Yamada, Yasuhide
Shimada, Yasuhiro
Boku, Narikazu
GASTRIC CANCER, 2017, 20 (04) : 655 - 662
[7] Second-line Chemotherapy in Advanced Gastric Cancer: Taxanes versus 5-FU-Based Treatment
Duzkopru, Yakup
Cilbir, Ebru
Imamoglu, Goksen Inanc
Dogan, Ozlem
Eren, Tulay
JCPSP-JOURNAL OF THE COLLEGE OF PHYSICIANS AND SURGEONS PAKISTAN, 2023, 33 (07): : 770 - 774
[8] Efficacy and safety of combination chemotherapy regimens containing taxanes for first-line treatment in advanced gastric cancer
Ma, Xiaoting
Zhang, Yujian
Wang, Cong
Yu, Jing
CLINICAL AND EXPERIMENTAL MEDICINE, 2023, 23 (02) : 381 - 396
[9] Non-platinum-based chemotherapy for treatment of advanced gastric cancer: 5-fluorouracil, taxanes, and irinotecan
Kang, Byung Woog
Kim, Jong Gwang
Kwon, Oh-Kyoung
Chung, Ho Young
Yu, Wansik
WORLD JOURNAL OF GASTROENTEROLOGY, 2014, 20 (18) : 5396 - 5402
[10] Non-platinum-based chemotherapy for treatment of advanced gastric cancer:5-fluorouracil,taxanes,and irinotecan
Byung Woog Kang
Jong Gwang Kim
Oh-Kyoung Kwon
Ho Young Chung
Wansik Yu
World Journal of Gastroenterology, 2014, 20 (18) : 5396 - 5402

← 1 2 3 4 5 →